Patents by Inventor Howard Gendelman

Howard Gendelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MRNAS ENCODING GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR FOR TREATING PARKINSON'S DISEASE
    Publication number: 20240123034
    Abstract: The disclosure features lipid nanoparticle (LNP) compositions comprising mRNA molecules encoding human granulocyte macrophage colony stimulating factor (GM-CSF) polypeptides and uses thereof in the treatment of Parkinson's Disease. The LNP compositions of the present disclosure comprise mRNA therapeutics encoding human GM-CSF for use in such treatment.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 18, 2024
    Inventors: Eric Yi-Chun Huang, Jared Iacovelli, Seymour De Picciotto, Sze-Wah Tse, Laurie Kenney, Katherine Olson, Howard Gendelman, Lee R. Mosley
  • CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT
    Publication number: 20230122226
    Abstract: Nucleic acids for use in CRISPR systems for treating HIV infections are disclosed. Pharmaceutical compositions incorporating the nucleic acids are disclosed as are methods of treating HIV using the nucleic acids.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 20, 2023
    Inventors: Howard Gendelman, Jonathan Herskovitz, Mahmudul Hasan
  • PRODRUGS AND FORMULATIONS THEREOF
    Publication number: 20220288037
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 15, 2022
    Inventors: Benson Edagwa, Howard Gendelman
  • ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
    Publication number: 20220211716
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 7, 2022
    Inventors: Howard Gendelman, Benson Edagwa
  • ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
    Publication number: 20220175936
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: November 27, 2019
    Publication date: June 9, 2022
    Inventors: Howard Gendelman, Benson Edagwa
  • Antiviral prodrugs and nanoformulations thereof
    Patent number: 11311547
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: April 26, 2022
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard Gendelman, Benson Edagwa
  • Antiviral prodrugs and nanoformulations thereof
    Patent number: 11166957
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: November 9, 2021
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard Gendelman, Benson Edagwa
  • Antiviral prodrugs and nanoformulations thereof
    Patent number: 11154557
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: October 26, 2021
    Assignee: Board of Regents of the University of Nebraska
    Inventors: Howard Gendelman, Benson Edagwa
  • ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
    Publication number: 20210322425
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: May 24, 2021
    Publication date: October 21, 2021
    Inventors: Howard Gendelman, Benson Edagwa
  • ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
    Publication number: 20210275535
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: May 24, 2021
    Publication date: September 9, 2021
    Inventors: Howard Gendelman, Benson Edagwa
  • ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF
    Publication number: 20210213023
    Abstract: The present invention provides prodrugs and methods of use thereof.
    Type: Application
    Filed: March 22, 2021
    Publication date: July 15, 2021
    Inventors: Howard Gendelman, Benson Edagwa
  • COMPOSITIONS FOR PROTEIN DELIVERY AND METHODS OF USE THEREOF
    Publication number: 20180303911
    Abstract: Compositions and methods for the delivery of a protein of interest are provided.
    Type: Application
    Filed: June 28, 2018
    Publication date: October 25, 2018
    Inventors: Alexander Kabanov, Tatiana Bronich, Elena Batrakova, Howard Gendelman
  • Compositions and methods for drug delivery
    Patent number: 9364443
    Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises an opsonin, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: June 14, 2016
    Assignees: BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE SA, BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Arnaud Beduneau, Howard Gendelman, Barrett Rabinow, Jane Werling
  • Method for delivering drugs to the brain
    Patent number: 9044381
    Abstract: The present invention is concerned with delivering a pharmaceutical composition to the brain of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the brain of a portion of the pharmaceutical composition by cells capable of reaching the brain. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytized or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the brain.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: June 2, 2015
    Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA, Board of Regents of the University of Nebraska by and Behalf of the University of Nebraska Medical Center
    Inventors: Barrett Rabinow, James E. Kipp, Howard Gendelman
  • Compositions for Protein Delivery and Methods of Use Thereof
    Publication number: 20100291065
    Abstract: Compositions and methods for the delivery of a protein of interest are provided.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 18, 2010
    Inventors: Alexander V. Kabanov, Tatiana Bronich, Elena Batrakova, Howard Gendelman
  • Compositions and Methods for Drug Delivery
    Publication number: 20090274765
    Abstract: The present disclosure is directed to surface-modified particles and to methods of making and using the same. The surface-modified particles comprise a particle core and a coating associated with the particle core, wherein the particle core comprises an active agent, the coating comprises an opsonin, and the surface-modified particle has an average size from about 1 nm to about 2,000 nm.
    Type: Application
    Filed: March 5, 2009
    Publication date: November 5, 2009
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A., BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Arnaud Beduneau, Howard Gendelman, Barrett Rabinow, Jane Werling
  • Method for delivering particulate drugs to tissues
    Publication number: 20060280430
    Abstract: The present invention is concerned with delivering a pharmaceutical composition to a tissue target of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the tissue target of a portion of the pharmaceutical composition by cells capable of reaching the tissue target. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytised or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the tissue target.
    Type: Application
    Filed: April 19, 2006
    Publication date: December 14, 2006
    Inventors: Barrett Rabinow, Howard Gendelman, James Kipp
  • Methods and compositions for the treatment of human immunodeficiency virus infection
    Publication number: 20050130128
    Abstract: Materials and methods are provided to inhibit HIV replication in targeted host cells.
    Type: Application
    Filed: December 10, 2003
    Publication date: June 16, 2005
    Inventors: Tsuneya Ikezu, Gary Leisman, Kimberly Carlson, Howard Gendelman
  • Method for delivering drugs to the brain
    Publication number: 20050048002
    Abstract: The present invention is concerned with delivering a pharmaceutical composition to the brain of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the brain of a portion of the pharmaceutical composition by cells capable of reaching the brain. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytised or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the brain.
    Type: Application
    Filed: June 15, 2004
    Publication date: March 3, 2005
    Inventors: Barrett Rabinow, James Kipp, Howard Gendelman